期刊文献+

PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making 被引量:6

PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making
下载PDF
导出
摘要 Since the first publication describing the identification of prostate-specific antigen (PSA) in the 1960s, much progress has been made. The PSA test changed from being initially a monitoring tool to being also used as a diagnostic tool. Over time, the test has been heavily debated due to its lack of sensitivity and specificity. However, up to now the PSA test is still the only biomarker for the detection and monitoring of prostate cancer. PSA-based screening for prostate cancer is associated with a high proportion of unnecessary testing and overdiagnosis with subsequent overtreatment. In the early years of screening for prostate cancer, high rates of uptake were very important. However, over time the opinion on PSA-based screening has shifted towards the notion of informed choice. Nowadays, it is thought to be unethical to screen men without them being aware of the pros and cons of PSA testing, as well as the fact that an informed choice is related to better patient outcomes. Now, as the results of three major screening studies have been presented and the downsides of screening are becoming better understood, informed choice is becoming more relevant. Since the first publication describing the identification of prostate-specific antigen (PSA) in the 1960s, much progress has been made. The PSA test changed from being initially a monitoring tool to being also used as a diagnostic tool. Over time, the test has been heavily debated due to its lack of sensitivity and specificity. However, up to now the PSA test is still the only biomarker for the detection and monitoring of prostate cancer. PSA-based screening for prostate cancer is associated with a high proportion of unnecessary testing and overdiagnosis with subsequent overtreatment. In the early years of screening for prostate cancer, high rates of uptake were very important. However, over time the opinion on PSA-based screening has shifted towards the notion of informed choice. Nowadays, it is thought to be unethical to screen men without them being aware of the pros and cons of PSA testing, as well as the fact that an informed choice is related to better patient outcomes. Now, as the results of three major screening studies have been presented and the downsides of screening are becoming better understood, informed choice is becoming more relevant.
机构地区 Department of Urology
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2011年第2期219-224,共6页 亚洲男性学杂志(英文版)
关键词 active surveillance informed decision making PSA testing shared decision making active surveillance informed decision making PSA testing shared decision making
  • 相关文献

参考文献60

  • 1Bangma CH. Indolent prostate cancer and active surveillance. Cancer World January- February 2010: 15-21.
  • 2van den Bergh RCN, Roemeling S, Roobol M J, Roobol W, Schr6der FH, Bangma CH. Prospective validation of active surveillance in prostate cancer:the PRIAS study. Eur Uro12007; 52: 1560-3.
  • 3Frocks RH, Urich VC, Patel CA, Opitz JM. Studies on the antigenic properties of prostatic tissues. J Uro11960; 84: 134-43.
  • 4Kouriefs C, Sahoyl M, Grange P, Muir G. Prostate-specific antigen through the years. Arch Ital Urol Andro12009; 81: 195-8.
  • 5Andriole GL, Crawford ED, Grubb RL3rd, Buys SS, Chia D etal. Mortality results from a randomized prostate-cancer screening trial. New EnEI J Med 2009; 360:1310-9.
  • 6H ugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A etal. Mortality results from the GOteborg randomised population-based prostate-cancer screeningtrial, lancetOncol 2010; 11: 725-732.
  • 7Costanza ME, Luckmann RS, Rosal M, White M J, Lapelle N etal. Helping men make an informed decision about prostate cancer screening: a pilot study of telephone counselling. Patient Educ Courts; e-pub ahead of print 14 January 2010; doi: 10.1016/j.pec.2010.05.011.
  • 8SchrSder FH. Review of diagnostic markers for prostate cancer. Recent Results Cancer Res2009~ 181= 173-82.
  • 9Thompson IM, Pauler DK, Goodman P J, Tangen CM, Lucia MS et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre. NewEnEIJMed2004; 350: 2239-46.
  • 10Evans R, Edwards AG, Elwyn G, Watson E, Grol R et al. 'It's a maybe test': men's experiences of prostate-specific antigen testing in primary care, BrJ Gen Pract2007; 57: 303-10.

同被引文献26

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部